MyoCell, a cell-based, autologous skeletal myoblast therapy for the treatment of cardiovascular diseases

H. Kh Haider, Y. Lei, Muhammad Ashraf

Research output: Contribution to journalReview article

23 Scopus citations


Cell therapy is fast emerging as a potential therapeutic option in cardiovascular therapeutics. Because of their inherent myogenic differentiation potential, skeletal myoblasts (SkMs) have been extensively assessed in preclinical and clinical studies for their feasibility, safety and effectiveness for myocardial repair. Bioheart Inc is developing MyoCell, autologous SkMs delivered by MyoCath and MyoStar catheter delivery systems, for the treatment of cardiovascular diseases such as myocardial infarction and congestive heart failure. MyoCell is undergoing phase II/III clinical development and has so far demonstrated safety and efficacy, including improvements in cardiac function in phase I/II clinical trials.

Original languageEnglish (US)
Pages (from-to)611-621
Number of pages11
JournalCurrent Opinion in Molecular Therapeutics
Issue number6
Publication statusPublished - Dec 1 2008
Externally publishedYes


ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery
  • Genetics(clinical)

Cite this